NA
AVLN

NVP Associates’s Avalyn Pharma AVLN Stock Holding History

NVP Associates’s Portfolio AVLN Stock Details AVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.7M Buy
+2,268,404
New +$65.5M 22.75% 2

Other funds holding AVLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

NVP Associates's AVLN Position: Q2 2026 in Review

NVP Associates opened a new position in Avalyn Pharma (AVLN) in Q2 2026: 2,268,404 shares worth $74.7M. The stake represents 22.75% of the portfolio and ranks #2 among its holdings.

15 funds tracked by Wall St. Rank hold AVLN as of Q2 2026.

  • NVP Associates held 2,268,404 shares of Avalyn Pharma worth $74.7M as of Q2 2026.
  • Avalyn Pharma was a new NVP Associates position in Q2 2026.
  • Avalyn Pharma made up 22.75% of NVP Associates's portfolio in Q2 2026, its #2 holding.
  • 15 funds tracked by Wall St. Rank held Avalyn Pharma as of Q2 2026.

Based on NVP Associates's 13F filing for Q2 2026, filed 7 Aug 2026.